IPSEN (OTCMKTS:IPSEY – Free Report) – HC Wainwright cut their FY2026 EPS estimates for shares of IPSEN in a research report issued on Friday, July 31st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $3.36 for the year, down from their previous estimate of $3.62. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IPSEN’s current full-year earnings is $3.84 per share.
Several other equities research analysts also recently weighed in on the company. Zacks Research upgraded IPSEN to a “hold” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Finally, Jefferies Financial Group downgraded shares of IPSEN to an “underperform” rating in a research note on Sunday. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.
IPSEN Trading Down 5.9%
Shares of OTCMKTS:IPSEY opened at $44.85 on Tuesday. IPSEN has a 12 month low of $30.05 and a 12 month high of $51.10. The firm’s 50-day moving average is $45.79 and its 200 day moving average is $45.61.
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Featured Stories
- Five stocks we like better than IPSEN
- 3 Drone Stocks That Should Soar After the Summer Slump
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
